About OcuCure Therapeutics
OcuCure Therapeutics is an ophthalmic pharmaceutical company developing new drugs. The company's lead compound has been formulated as a topical eye drop for both Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). AMD and DR are leading causes of blindness in developed countries. Additionally, the lead compound has potential for use as a prophylactic. The presence of the therapeutic target has been validated in human AMD and DR tissues. This confirms the OcuCure approach for treating ocular angiogensis. The topical eye drop also has demonstrated the ability to cross human corneas in in vitro studies. When the eye drop was administered to animals, the lead compound penetrated all the way back to the retina at clinically significant concentrations without any toxic effects observed. By comparison, the currently available drugs for AMD are administered by a monthly injection into the eye.
Missing: OcuCure Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: OcuCure Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing OcuCure Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
OcuCure Therapeutics is included in 2 Expert Collections, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
OcuCure Therapeutics Frequently Asked Questions (FAQ)
When was OcuCure Therapeutics founded?
OcuCure Therapeutics was founded in 2005.
Where is OcuCure Therapeutics's headquarters?
OcuCure Therapeutics's headquarters is located at 15 East Salem Avenue, Roanoke.
What is OcuCure Therapeutics's latest funding round?
OcuCure Therapeutics's latest funding round is Unattributed - X.
How much did OcuCure Therapeutics raise?
OcuCure Therapeutics raised a total of $3.85M.
Who are the investors of OcuCure Therapeutics?
Investors of OcuCure Therapeutics include Carilion Biomedical Institute.
Who are OcuCure Therapeutics's competitors?
Competitors of OcuCure Therapeutics include Alimera Sciences, OcuNexus Therapeutics, Novexel, Xanodyne Pharmaceuticals, Dow Pharmaceutical Sciences and 12 more.
Compare OcuCure Therapeutics to Competitors
Phylogix is an early-stage pharmaceutical company developing chemoprotectant compounds.
An R&D company focusing on technologies in imaging. Predictek analyzes functional brain images for the pharmaceutical industry, and is developing a new kind of multispectral imaging for use by eye care professionals.
TheraQuest Biosciences, Inc. is building a diversified portfolio of pharmaceutical products to address pain management.
NeurOp is a biopharmaceutical company developing new medicines to treat central nervous system disorders, including major depression, neuropathic pain and ischemia. The company's mission is to develop a new generation of N-methyl-D-aspartate (NMDA) receptor blockers, which inhibit proteins that play an important role in neuron signaling. Its compounds specifically target the NR2B subtype of these receptors offering an unprecedented opportunity to improve the safety and tolerability of this therapeutic class without compromising efficacy.
TERAPIA is a company engaged in the development and sale of pharmaceutical products
greece vacation pharmaceutical company athens hotel naxos pharma travel tour
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.